Value of somatostatin receptor PET/CT in MEN1 patients at various stages of their disease.
Fiche publication
Date publication
décembre 2021
Journal
The Journal of clinical endocrinology and metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio
Tous les auteurs :
Mennetrey C, Le Bras M, Bando-Delaunay A, Al-Mansour L, Haissaguerre M, Batisse-Lignier M, Ouvrard E, Ansquer C, Walter T, de Mestier L, Kelly A, Tlili G, Giraud S, North MO, Odou MF, Goichot B, Cuny T, Loundou A, Romanet P, Imperiale A, Taïeb D
Lien Pubmed
Résumé
Despite the growing evidence of the clinical value of somatostatin receptor (SSTR) PET in the evaluation of neuroendocrine tumors/NET, its role remains to be clarified at different time points in the MEN1 patient journey. The rareness of the disease is however a significant impediment to prospective clinical trials.
Mots clés
Gallium-68 labeled somatostatin analogs, MEN1, Positron emission tomography, genetics, neuroendocrine tumors, somatostatin receptors
Référence
J Clin Endocrinol Metab. 2021 Dec 23;: